Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
NCT06526858
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Resistant Hypertension
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 22 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- DeepQure Inc.
- Last updated on ClinicalTrials.gov
- August 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- University of California Irvine · Orange, CA
- Stanford Health Care · Stanford, CA
Florida · 1
- University of Florida College of Medicine · Gainesville, FL
Georgia · 1
- Emory University Hospital · Atlanta, GA
Michigan · 1
- Henry Forth Health · Detroit, MI
Minnesota · 1
- Mayo Clinic · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.